SBL
ZOM

Sargent Bickham Lagudis’s Zomedica Corp. ZOM Stock Holding History

Sargent Bickham Lagudis’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,700
Closed -$1K – 1054
2021
Q4 		$1K Buy
+1,700
New +$766 ﹤0.01% 948

Other funds holding ZOM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Sargent Bickham Lagudis's ZOM Position: Q1 2022 in Review

Sargent Bickham Lagudis sold out of Zomedica Corp. (ZOM) in Q1 2022, closing a stake of 1,700 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in ZOM in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 110 funds tracked by Wall St. Rank hold ZOM as of Q1 2022.

  • Sargent Bickham Lagudis reported no remaining Zomedica Corp. position as of Q1 2022 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 1,700 Zomedica Corp. shares in Q1 2022, an estimated $1K.
  • Sargent Bickham Lagudis first reported a position in Zomedica Corp. in Q4 2021 and held it in 1 quarter.
  • Sargent Bickham Lagudis's Zomedica Corp. position peaked at $1K in Q4 2021.
  • 110 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2022, filed 27 Apr 2022.